(PTHL) Pheton Holdings Ordinary - Ratings and Ratios

Pheton Holdings Ltd (NASDAQ:PTHL) is a healthcare solutions provider specializing in brachytherapy, a precision radiation therapy that targets cancer cells by placing radioactive sources inside the body. The companys flagship product, FTTPS (Pheton Treatment Planning System), is a proprietary software designed to optimize brachytherapy treatments for various cancers. FTTPS enables precise calculation of target volumes, prescription doses, and organ-at-risk limitations, ensuring personalized and effective dose distribution plans. Founded in 1998 and headquartered in Beijing, China, Pheton Holdings operates as a subsidiary of ZJW (BVI) LTD, focusing on advancing cancer treatment technologies. The companys solutions are integral to modern oncology, addressing the growing demand for accurate and minimally invasive cancer therapies.

Based on and , Pheton Holdings Ltds stock (PTHL) is expected to face continued downward pressure over the next three months. The stocks 20-day average volume of 74,296 indicates moderate trading activity, while its last price of $2.17 reflects a decline from its 20-day SMA of $2.51. The 50-day SMA of $3.29 and 200-day SMA of $4.02 signal a sustained downtrend. With an ATR of 0.47, volatility is expected to remain moderate. Fundamentally, the companys negative RoE of -78.76% and high P/B ratio of 2317.29 raise concerns about profitability and valuation. While the forward P/E is 0.00, indicating potential future earnings, the current P/S ratio of 97.29 suggests high valuation relative to sales. Overall, PTHL is likely to remain under pressure, with potential price targets near $2.00 as the stock continues to trend below its key moving averages.